Delivery Order SPE2DB20D3505-SPE2DB21FU4C9
- Not listed
- This federal contract award is for Sertraline HCL 100 mg tablets, a generic pharmaceutical product, valued at $1,863.60. The award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on September 21, 2022. This contract is a delivery order with a firm fixed price pricing type and does not have a set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., which serves as a critical...
- This federal contract award, with ID SPE2DX15D3005|SPE2DX24F3RDZ, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $31,957.90 firm fixed-price delivery order covers the supply of 4,564,452 units of 100 mg Sertraline HCL tablets, a medication used to treat mental health conditions. The contract has an ultimate completion date of May 1, 2024. Amerisourcebergen holds a significant $999,999,999...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a pharmaceutical distribution company. The contract, valued at $1,008.25, is for the delivery of Sertraline HCL 100 mg tablets. The award is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC, valued at up to $999,999,999.00, serves as the primary vehicle for Cencora,...
- This federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is for the delivery of Sertraline HCL 100 mg tablets. The $23,592.70 delivery order has a firm fixed-price contract type and an ultimate completion date of March 7, 2024. This award is not associated with a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that plays a critical role in supplying...
- This federal contract award, with ID SPE2DB20D3111|SPE2DB23FB0FB, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a division of the parent company Cencora, Inc. The $2,227.92 firm-fixed-price delivery order is for the supply of 4562242511 - SERTRALINE HCL 100 MG TABLET UD 100S, a generic pharmaceutical product. The award is not designated under any set-aside program, indicating open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that...
- This is a $1,085.40 federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution company. The contract is a Delivery Order for the supply of 500 count bottles of 100 mg Sertraline HCL tablets. The contract has an ultimate completion date of October 31, 2024 and is a Firm Fixed Price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued at...
- This federal contract is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical sourcing and distribution company Amerisourcebergen Corporation. The contract is for the supply of 4,563,791 units of Sertraline HCL 100 mg tablets, with a firm fixed price of $1,586.88 and a period of performance through February 29, 2024. This delivery order is issued under an indefinite delivery contract (IDC) held by...
- This federal contract award, with an ID of SPE2DB20D3101|SPE2DB24FRVA3, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,081.20, is for the delivery of 4,565,828,073 units of the drug Sertraline HCL 100 mg tablets. The contract is a Firm Fixed Price Delivery Order, with a period of performance running through September 17, 2024. This award does not have a set-aside...
- This federal contract award, valued at $2,131.69, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under an existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,390.68 firm fixed-price delivery order contract is to supply 4,557,963,840 units of the medication Sertraline HCL 100 mg tablets. The award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., valued at up to $999,999,999.00 through November 2026....
- SPE2DB20D3505Indefinite Delivery Contract
- SPE2DB20D3505-SPE2DB21FU4C9Delivery Order
This federal contract award, identified as SPE2DB20D3505|SPE2DB21FU4C9, was granted by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $1,005.72 delivery order is for the supply of Sertraline HCL 100 mg tablets, a generic medication used to treat mental health conditions. The contract is a firm fixed-price Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This single-award IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military treatment facilities, veterans' healthcare programs, and other federal medical institutions worldwide. The contract does not have a set-aside designation, indicating open competition. In addition to the DLA contract, Amerisourcebergen also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs. These contracts demonstrate the company's critical role as a major pharmaceutical distributor and healthcare solutions provider to various federal government agencies.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 9/8/21 |